Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2017 09:00 ET | Source: Immuron Limited

Travelan Experiences Strong Q1 FY2018 Sales Growth

Key Highlights: Significant growth of sales for Immuron’s over-the-counter supplement Travelan® for Q1 2018 compared to Q1 2017 Travelan® US experienced a 197% increase in sales compared to Q1...
October 17, 2017 08:53 ET | Source: Immuron Limited

Immuron Ltd. Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections

MELBOURNE, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral...
September 19, 2017 08:00 ET | Source: Immuron Limited

Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions

Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment Company provides overview of...
August 15, 2017 09:15 ET | Source: Immuron Limited

Immuron Commences US Non-Deal Institutional Investor Roadshow

MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...
August 09, 2017 08:30 ET | Source: Immuron Limited

Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)

Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...
July 10, 2017 08:30 ET | Source: Immuron Limited

NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability

MELBOURNE, Australia, July 10, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company, Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is pleased to announce safety and efficacy results of the...
June 08, 2017 17:43 ET | Source: Immuron Limited

Immuron Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing – Raising US $6.1 Million

MELBOURNE, Australia, June 08, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN), today announced the pricing of its initial public offering in...
April 18, 2017 14:31 ET | Source: Immuron Limited

Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies

Significant and clear beneficial biological effect of IMM-124E in the Acute Colitis modelResults add to the already existing body of evidence of IMM-124E’s strong anti-inflammatory properties ...
February 20, 2017 09:59 ET | Source: Immuron Limited

Immuron Completes Phase II NASH Clinical Trial Recruitment

MELBOURNE, Australia, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to...
January 19, 2017 10:00 ET | Source: Immuron Limited

Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University

MELBOURNE, Australia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce the initiation of several studies designed to add to the...